NCT07246161RecruitingPhase 2
Detection of Orally Delivered Probiotic Strains in the Vaginal Microbiome of Healthy Female Adults
Lallemand Health Solutions1 site in 1 country72 target enrollmentStarted: October 20, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- Presence or absence of probiotic stains in vaginal swabs after 28 days of oral intake
Study Overview
Brief Summary
The purpose of the present study is to obtain more information on the transit of orally ingested probiotics to the vagina.
Detailed Description
Probiotics have emerged as novel supplements to support women's health, demonstrating benefits in maintain vaginal health and promoting recovery from dysbiosis. This includes various oral and vaginal probiotics shown to alleviate symptoms and enhance the reversal of vaginal dysbiosis.
Oral delivered probiotic strains suggest their ability to migrate and transiently colonize the vagina to support vaginal health but is not well understood. Therefore, this study will aim to provide additional information on their transit to the vagina.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Clinically healthy female between the ages of 18 and 50 years, inclusive,
- •have a regular or predictable menstrual cycle
- •Typically have regular bowel movements,
- •Willing and able to consume a probiotic supplement for 4 weeks,
- •Willing to discontinue consumption of probiotic supplement and probiotic-fortified products 2 weeks before the start of the study and throughout the study,
- •Willing to discontinue fiber supplements 2 weeks before the start of the study, and throughout the study,
- •Willing to provide 1 stool sample 4 times throughout the study,
- •Willing to provide 2 vaginal swabs 4 times throughout the study,
- •Willing to undergo vaginal pH swab measurements (with a swab) 5 times throughout the study,
- •Willing to provide 2 perineal skin swabs (skin between the vagina and the anus) 3 times throughout the study,
- •Willing to complete a pregnancy test at the screening visit.
Exclusion Criteria
- •Menopausal women,
- •Vaginal pH < 2 or > 5 measured at screening,
- •. Menstruation during the sample collection times,
- •Women that are lactating, pregnant, attempting to get pregnant, or have a positive pregnancy test,
- •Use of vaginal probiotics in the last 3 months,
- •Use of local vaginal antibiotics or antifungals in the last 3 months.
- •Use of oral antibiotics or antifungals in the last month,
- •Ongoing symptoms of vaginal and/or urinary tract infections,
- •Current treatment for vaginal sepsis or urosepsis,
- •Currently being treated for a severe chronic disease (e.g. cancer, renal failure, chronic inflammatory digestive or gastro-intestinal disease, immunodeficiency, etc.),
- •Clinical diagnosis of a gynecological disease or condition (e.g, fibroma, endometriosis, polycystic ovarian syndrome, etc.),
- •Clinical diagnosis of secondary dysmenorrhea,
- •Intolerance, allergy or sensitivity to milk, soy, or yeast.
Arms & Interventions
Group 2
Experimental
Intervention: Probiotic Formula 2 (Other)
Group 3
Experimental
Intervention: Probiotic Formula 3 (Other)
Group 1
Experimental
Intervention: Probiotic Formula 1 (Other)
Outcomes
Primary Outcomes
Presence or absence of probiotic stains in vaginal swabs after 28 days of oral intake
Time Frame: 28 days of oral intake
Secondary Outcomes
- Viability of the probiotic strains recovered from vaginal swabs at days 0, 14, and 28 of oral intake, and 1 week after the end of the intervention (Day 35)(From enrollment to the 35th day.)
- Viability of the probiotic strains recovered from perineal skin swabs at day 0, 14, and 28 of oral intake.(From enrollment to 28th day)
- Presence or absence of the probiotic stains in the vaginal swabs at days 0 & 14 of oral intake, and 1 week after the end of intervention (Day 35)(From enrollment to day 35)
- Presence or absence of the probiotic strains in perineal skin swabs at days 0, 14, and 28 of oral intake.(From enrollment to the 28th day.)
- Presence or absence of the probiotic strains in stool samples at days 0, 14 and 28 of oral intake.(From enrollment to 28th day)
- Changes in vaginal pH from baseline to 1 week after the end of the intervention (Day 35)(From baseline to day 35.)
- Changes in the abundance of endogenous and pathogenic bacterial and fungal species in the vagina at days 0, 14, 28 and 35.(From enrollment to the 35th day)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Global Effects of a Probiotic Strain on Lactating WomenMastitisNCT01124448Universidad Complutense de Madrid40
Unknown
Phase 1
Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza VaccinesInfluenzaNCT00294788Probiomics Ltd300
Unknown
Not Applicable
The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing EnterocolitisDeathNecrotizing EnterocolitisNCT02552706Shenzhen Bao'an Maternal and Child Health Hospital270
Completed
Not Applicable
Effect of a Probiotic Water on Oral Health in AdultsOral BacteriaHalitosisNCT04473404Dose Biosystems Inc.48
Completed
Not Applicable
Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.Late Onset Neonatal SepsisInfant, Very Low Birth WeightNecrotizing EnterocolitisNCT02073214IBSS Biomed S.A.182